Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NEO 
NeoGenomics Inc (NEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NEO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $10
1 Year Target Price $10
| 6 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.26% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.05B USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 14 | Beta 1.61 | 52 Weeks Range 4.72 - 19.11 | Updated Date 09/17/2025 |
52 Weeks Range 4.72 - 19.11 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.1% | Operating Margin (TTM) -15.43% |
Management Effectiveness
Return on Assets (TTM) -3.25% | Return on Equity (TTM) -11.76% |
Valuation
Trailing PE - | Forward PE 222.22 | Enterprise Value 1280215189 | Price to Sales(TTM) 1.52 |
Enterprise Value 1280215189 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 1.86 | Enterprise Value to EBITDA -27.92 | Shares Outstanding 129178622 | Shares Floating 119992730 |
Shares Outstanding 129178622 | Shares Floating 119992730 | ||
Percent Insiders 1.29 | Percent Institutions 100.33 |
Upturn AI SWOT
NeoGenomics Inc
Company Overview
History and Background
NeoGenomics Inc. was founded in 2001. Initially focused on cytogenetics, it expanded into molecular testing and became a leading provider of cancer testing services. Significant milestones include acquisitions and strategic partnerships to broaden its testing portfolio and geographic reach.
Core Business Areas
- Oncology Testing Services: Provides comprehensive genetic and molecular testing services to oncologists, pathologists, and pharmaceutical companies to aid in cancer diagnosis, prognosis, and treatment decisions.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives. The organizational structure includes departments for R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Comprehensive Oncology Testing: Includes a wide range of tests, such as next-generation sequencing (NGS), FISH, IHC, and flow cytometry, used for cancer diagnosis and treatment. Market share varies across specific tests, but NeoGenomics is a significant player in the oncology testing market. Exact market share data is difficult to pin down due to industry dynamics. Competitors include Quest Diagnostics (DGX), Labcorp (LH), and Exact Sciences (EXAS).
- Pharma Services: Offers services to pharmaceutical companies, including biomarker discovery, clinical trial support, and companion diagnostics development. Market share data for pharma services is not publicly available. Competitors in this space include Charles River Laboratories (CRL) and ICON (ICLR).
Market Dynamics
Industry Overview
The oncology testing industry is experiencing rapid growth, driven by advancements in genomic technologies, increasing cancer incidence, and the development of personalized medicine approaches.
Positioning
NeoGenomics Inc. is positioned as a leading provider of oncology testing services, with a strong focus on innovation and customer service. Its competitive advantages include its comprehensive test menu, advanced technologies, and experienced team.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics is estimated to be in the tens of billions of dollars and is expected to continue growing. NeoGenomics Inc. is positioned to capture a significant share of this market through its comprehensive testing services and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Comprehensive test menu
- Advanced technologies
- Experienced team
- Strong brand reputation
- Extensive customer base
Weaknesses
- Dependence on reimbursement rates
- Intense competition
- Potential regulatory changes
- Integration challenges post-acquisition
Opportunities
- Expanding into new geographic markets
- Developing new tests and services
- Partnering with pharmaceutical companies
- Leveraging data analytics
- Growth in liquid biopsy testing
Threats
- Competition from larger players
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturn
- Data security breaches
Competitors and Market Share
Key Competitors
- DGX
- LH
- EXAS
Competitive Landscape
NeoGenomics Inc. competes with a mix of large diagnostic companies and specialized oncology testing providers. Its competitive advantage lies in its comprehensive test menu and focus on customer service.
Major Acquisitions
Clarient
- Year: 2015
- Acquisition Price (USD millions): 280
- Strategic Rationale: Expanded NeoGenomics' reach into hematopathology and anatomic pathology.
Growth Trajectory and Initiatives
Historical Growth: NeoGenomics Inc. has experienced significant growth in revenue and test volume over the past several years.
Future Projections: Future growth is expected to be driven by increasing demand for oncology testing, advancements in genomic technologies, and strategic acquisitions.
Recent Initiatives: Recent strategic initiatives include expanding its test menu, investing in new technologies, and partnering with pharmaceutical companies.
Summary
NeoGenomics Inc. is a key player in the oncology testing market, showing promising growth and a commitment to innovation. However, it faces stiff competition and relies on reimbursement rates. Its diverse testing menu and customer focus are strengths, while adaptability to market changes is vital. Future success depends on navigating regulatory landscapes and continued advancements in personalized medicine.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share data are estimates and may vary. Financial metrics can change based on current fiscal year data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeoGenomics Inc
Exchange NASDAQ | Headquaters Fort Myers, FL, United States | ||
IPO Launch date 1999-11-02 | CEO & Director Mr. Anthony P. Zook | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2200 | Website https://www.neogenomics.com |
Full time employees 2200 | Website https://www.neogenomics.com | ||
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.